Adjuvant and Salvage Radiation Therapy After Prostatectomy: American Society for Radiation Oncology/American Urological Association Guidelines

      Purpose

      The purpose of this guideline was to provide a clinical framework for the use of radiation therapy after radical prostatectomy as adjuvant or salvage therapy.

      Methods and Materials

      A systematic literature review using PubMed, Embase, and Cochrane database was conducted to identify peer-reviewed publications relevant to the use of radiation therapy after prostatectomy. The review yielded 294 articles; these publications were used to create the evidence-based guideline statements. Additional guidance is provided as Clinical Principles when insufficient evidence existed.

      Results

      Guideline statements are provided for patient counseling, use of radiation therapy in the adjuvant and salvage contexts, defining biochemical recurrence, and conducting a restaging evaluation.

      Conclusions

      Physicians should offer adjuvant radiation therapy to patients with adverse pathologic findings at prostatectomy (ie, seminal vesicle invastion, positive surgical margins, extraprostatic extension) and salvage radiation therapy to patients with prostate-specific antigen (PSA) or local recurrence after prostatectomy in whom there is no evidence of distant metastatic disease. The offer of radiation therapy should be made in the context of a thoughtful discussion of possible short- and long-term side effects of radiation therapy as well as the potential benefits of preventing recurrence. The decision to administer radiation therapy should be made by the patient and the multidisciplinary treatment team with full consideration of the patient's history, values, preferences, quality of life, and functional status. The American Society for Radiation Oncology and American Urological Association websites show this guideline in its entirety, including the full literature review.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. American Cancer Society: Prostate cancer key statistics. 2009. Available at: http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics; Accessed November 3 2012.

        • Amling C.L.
        • Blute M.L.
        • Bergstralh E.J.
        • et al.
        Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
        J Urol. 2000; 164: 101-105
        • Chun F.K.
        • Graefen M.
        • Zacharias M.
        • et al.
        Anatomic radical retropubic prostatectomy–long-term recurrence-free survival rates for localized prostate cancer.
        World J Urol. 2005; 24: 273-280
        • Han M.
        • Partin A.W.
        • Pound C.R.
        • et al.
        Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience.
        Urol Clin North Am. 2001; 28: 555-565
        • Bianco Jr., F.J.
        • Scardino P.T.
        • Eastham J.A.
        Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”).
        Urology. 2005; 66: 83-94
        • Stephenson A.J.
        • Scardino P.T.
        • Eastham J.A.
        • et al.
        Preoperative nomogram predicting for the 10-year probability of prostate cancer recurrence after radical prostatectomy.
        J Natl Cancer Inst. 2006; 98: 715-717
        • Swindler P.
        • Eastham J.A.
        • Ohori M.
        • et al.
        Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
        J Urol. 2005; 174: 903-907
        • Kupelian P.A.
        • Katcher J.
        • Levin H.S.
        • et al.
        Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 1997; 377: 1043-1052
        • Lee H.M.
        • Solan M.J.
        • Lupinacci P.
        • et al.
        Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiation therapy.
        Urology. 2004; 64: 84-89
        • Ohori M.
        • Wheeler T.M.
        • Kattan M.W.
        • et al.
        Prognostic significance of surgical margins in radical prostatectomy specimens.
        J Urol. 1995; 154: 1818-1824
        • Lowe B.A.
        • Lieberman S.F.
        Disease recurrence and progression in unrelated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy.
        J Urol. 1997; 158: 1452-1456
        • Pound C.R.
        • Partin A.W.
        • Eisenberger M.A.
        • et al.
        Natural history of progression after PSA elevation following radical prostatectomy.
        JAMA. 1999; 281: 1591-1597
        • Thompson Jr., I.M.
        • Tangen C.M.
        • Paradelo J.
        • et al.
        Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
        JAMA. 2006; 296: 2329-2335
        • Bolla M.
        • van Poppel H.
        • Collette L.
        • et al.
        Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).
        Lancet. 2005; 366: 572-578
        • Wiegel T.
        • Bottke D.
        • Steiner U.
        • et al.
        Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
        J Clin Oncol. 2009; 27: 2924-2930
        • Bernard Jr., J.R.
        • Buskirk S.J.
        • Heckman M.G.
        • et al.
        Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.
        Int J Radiat Oncol Biol Phys. 2010; 76: 735-740
        • Cozzarini C.
        • Montorsi F.
        • Fiorino C.
        • et al.
        Need for high radiation dose (greater-than or equal to 70 Gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
        Int J Radiat Oncol. 2009; 75: 966-974
        • King C.R.
        • Spiotto M.T.
        Improved outcomes with higher doses for salvage radiotherapy after prostatectomy.
        Int J Radiat Oncol Biol Phys. 2008; 71: 23-27
        • Siegmann A.
        • Bottke D.
        • Faehndrich J.
        • et al.
        Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study.
        Strahlenther Onkol. 2011; 187: 467-472
        • Ohri N.
        • Dicker A.
        • Trabulsi E.
        • et al.
        Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modeling.
        Eur J Cancer. 2012; 48: 837-844
        • Michalski J.M.
        • Lawton C.
        • El Naqa I.
        • et al.
        Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2010; 76: 361-368
        • Sidhom M.A.
        • Kneebone A.B.
        • Lehman M.
        • et al.
        Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group.
        Radiother Oncol. 2008; 88: 10-19
        • Wiltshire K.L.
        • Brock K.K.
        • Haider M.A.
        • et al.
        Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 2007; 69: 1090-1099
        • Poortmans P.
        • Bossi A.
        • Vandeputte K.
        • et al.
        Guidelines for target volume definition in postoperative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group.
        Radiother Oncol. 2007; 84: 121-127
        • Bolla M.
        • van Poppel H.
        • Tombal B.
        • et al.
        Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomized controlled trial (EORTC trial 22911).
        Lancet. 2012; 380: 2018-2027
        • Thompson I.M.
        • Tangen C.M.
        • Paradelo J.
        • et al.
        Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial.
        J Urol. 2009; 181: 956-962
        • Albertsen P.C.
        • Hanley J.A.
        • Penson D.F.
        • et al.
        Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation.
        J Urol. 2004; 171: 2221-2225
        • Swanson G.P.
        • et al.
        Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.
        J Clin Oncol. 2007; 25: 2225
        • Shinghal R.
        • Yemoto C.
        • McNeal J.E.
        • et al.
        Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen.
        Urology. 2003; 61: 380-385
        • Dotan Z.A.
        • Bianco Jr., F.J.
        • Rabbani F.
        • et al.
        Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy.
        J Clin Oncol. 2005; 23: 1962-1968
        • Boorjian S.A.
        • Karnes R.J.
        • Crispen P.L.
        • et al.
        Radiation therapy after radical prostatectomy: impact on metastasis and survival.
        J Urol. 2009; 182: 2708-2715
        • Trock B.J.
        • Han M.
        • Freedland S.J.
        • et al.
        Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
        JAMA. 2008; 299: 2760-2769
        • King C.R.
        The timing of salvage radiotherapy after radical prostatectomy: a systematic review.
        Int J Radiat Oncol Biol Phys. 2012; 84: 104-111
        • Ohri N.
        • Dicker A.
        • Trabulsi E.
        • et al.
        Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modeling.
        Eur J Cancer. 2012; 48: 837-844
        • Alongi F.
        • Fiorino C.
        • Cozzarini C.
        • et al.
        IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with postoperative adjuvant or salvage radiotherapy after radical prostatectomy.
        Radiother Oncol. 2009; 93: 207-212
        • Goenka A.
        • Magsanoc J.M.
        • Pei X.
        • et al.
        Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
        Eur Urol. 2011; 60: 1142-1148
        • Ost P.
        • Lumen N.
        • Goessaert A.S.
        • et al.
        High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after RP for rising or persisting prostate-specific antigen: 5-year results.
        Eur Urol. 2011; 60: 842-849

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.